Doliver Capital Advisors LP reduced its stake in AbbVie Inc (NYSE:ABBV) by 2.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,665 shares of the company’s stock after selling 297 shares during the period. AbbVie makes up about 0.6% of Doliver Capital Advisors LP’s holdings, making the stock its 16th largest holding. Doliver Capital Advisors LP’s holdings in AbbVie were worth $1,168,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Allred Capital Management LLC acquired a new stake in AbbVie in the fourth quarter valued at $1,055,000. Parkside Financial Bank & Trust raised its stake in AbbVie by 6.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 11,541 shares of the company’s stock valued at $1,064,000 after buying an additional 714 shares in the last quarter. WESPAC Advisors LLC acquired a new stake in AbbVie in the fourth quarter valued at $2,966,000. Exane Derivatives raised its stake in AbbVie by 441.2% in the fourth quarter. Exane Derivatives now owns 48,325 shares of the company’s stock valued at $4,454,000 after buying an additional 39,395 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in AbbVie by 7.0% in the fourth quarter. Handelsbanken Fonder AB now owns 562,326 shares of the company’s stock valued at $51,841,000 after buying an additional 36,985 shares in the last quarter. Institutional investors and hedge funds own 69.58% of the company’s stock.

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 15,797 shares of AbbVie stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $79.03, for a total value of $1,248,436.91. Following the sale, the executive vice president now owns 93,312 shares of the company’s stock, valued at approximately $7,374,447.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Vice Chairman Laura J. Schumacher sold 25,000 shares of AbbVie stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $90.00, for a total value of $2,250,000.00. Following the completion of the sale, the insider now directly owns 134,322 shares in the company, valued at approximately $12,088,980. The disclosure for this sale can be found here. Insiders sold a total of 90,797 shares of company stock worth $7,748,437 in the last ninety days. 0.07% of the stock is owned by corporate insiders.

Several equities analysts have issued reports on the company. ValuEngine raised AbbVie from a “strong sell” rating to a “sell” rating in a report on Friday, March 15th. Barclays reaffirmed a “hold” rating and set a $86.00 price objective on shares of AbbVie in a report on Thursday, February 14th. Credit Suisse Group set a $79.00 price objective on AbbVie and gave the stock a “hold” rating in a report on Friday, January 25th. Zacks Investment Research lowered AbbVie from a “buy” rating to a “hold” rating in a report on Wednesday, January 23rd. Finally, UBS Group reaffirmed a “neutral” rating and set a $91.00 price objective (down previously from $97.00) on shares of AbbVie in a report on Wednesday, January 23rd. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $94.48.

NYSE ABBV opened at $80.43 on Thursday. AbbVie Inc has a 52-week low of $75.77 and a 52-week high of $113.79. The stock has a market cap of $119.22 billion, a P/E ratio of 10.22, a P/E/G ratio of 1.22 and a beta of 1.17.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, January 25th. The company reported $1.90 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.92 by ($0.02). AbbVie had a negative return on equity of 439.07% and a net margin of 17.36%. The company had revenue of $8.31 billion for the quarter, compared to analysts’ expectations of $8.37 billion. During the same period in the prior year, the business earned $1.48 EPS. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. As a group, analysts expect that AbbVie Inc will post 8.68 EPS for the current year.

AbbVie announced that its Board of Directors has authorized a share buyback plan on Thursday, December 13th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 3.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be issued a dividend of $1.07 per share. This represents a $4.28 dividend on an annualized basis and a dividend yield of 5.32%. The ex-dividend date is Friday, April 12th. AbbVie’s dividend payout ratio is currently 54.11%.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2019/03/21/doliver-capital-advisors-lp-has-1-17-million-stake-in-abbvie-inc-abbv.html.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C.

Recommended Story: Is a Roth IRA right for you?

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.